Iceland vs Malaysia: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Iceland
92.0%
in 2025
Malaysia
93.0%
in 2025
Iceland rank
54th
Malaysia rank
51st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Iceland
- Malaysia
How they compare
Malaysia currently reports 93.0% against 92.0% in Iceland, a difference of 1.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Malaysia ahead.
Iceland ranks 54th and Malaysia ranks 51st of 192 countries.
Iceland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iceland | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 71.6% | 0.0% | 71.6% | Iceland |
| 2020s | 91.0% | 73.3% | 17.7% | Iceland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Iceland or Malaysia?
- Malaysia, at 93.0% against 92.0% in Iceland as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Iceland and Malaysia?
- 1.0%, with Malaysia ahead.
- How many years of comparable data are there for Iceland and Malaysia?
- 18 years are reported by both, from 2008 to 2025.
- How do Iceland and Malaysia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Iceland ranks 54th and Malaysia ranks 51st of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.